AT165549B - Process for the production of hemostatically acting plugs and bandages - Google Patents

Process for the production of hemostatically acting plugs and bandages

Info

Publication number
AT165549B
AT165549B AT165549DA AT165549B AT 165549 B AT165549 B AT 165549B AT 165549D A AT165549D A AT 165549DA AT 165549 B AT165549 B AT 165549B
Authority
AT
Austria
Prior art keywords
sep
thrombin
solution
plugs
gelatin
Prior art date
Application number
Other languages
German (de)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of AT165549B publication Critical patent/AT165549B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/32Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42Use of materials characterised by their function or physical properties
    • A61L15/425Porous materials, e.g. foams or sponges
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42Use of materials characterised by their function or physical properties
    • A61L15/64Use of materials characterised by their function or physical properties specially adapted to be resorbable inside the body
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08JWORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J9/00Working-up of macromolecular substances to porous or cellular articles or materials; After-treatment thereof
    • C08J9/28Working-up of macromolecular substances to porous or cellular articles or materials; After-treatment thereof by elimination of a liquid phase from a macromolecular composition or article, e.g. drying of coagulum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00Materials characterised by their function or physical properties
    • A61L2400/04Materials for stopping bleeding
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08JWORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J2389/00Characterised by the use of proteins; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)

Description

       

   <Desc/Clms Page number 1> 
 



  Verfahren zur Herstellung von hämostatisch wirkenden Pfropfen und Verbänden 
In der Chirurgie werden bereits hämostatisch wirkende, aus Fibrin-und CellulosederivatSchwämmen bestehende Pfropfen und Verbände benützt, die eine Thrombinlösung enthalten. Diese Pfropfen und Verbände werden so gebrauchsfertig gemacht, dass man sie unmittelbar vor der Verwendung in die Thrombinlösung eintaucht. Diese Verwendung macht es notwendig, dass die Schwämme aus wasserunlöslichem Material hergestellt werden, da sie sonst bei der Benetzung mit der Thrombinlösung zusammenfallen würden. Solche Schwämme haben den grossen Nachteil, dass sie vom Organismus bedeutend schlechter resorbiert werden als lösliche Substanzen. 



   Um diesem Nachteil zu begegnen, verwenden verschiedene Autoren statt diese Schwämme lösliche Gelatine-Gelee, die sie kurz vor Gebrauch in eine Thrombinlösung eintauchen. Die Durchtränkung eines solchen Gelees mit der Thrombinlösung ist aber schwierig und verläuft sehr langsam ; ferner können die Pfropfen und Verbände, wenn sie mit der Thrombinlösung vollgesogen sind, nicht lange aufbewahrt werden, da das Thrombin in Gegenwart von Wasser nicht stabil ist und sehr rasch an Wirksamkeit verliert. Ausserdem wurde festgestellt, dass das Thrombin eine Verminderung des Geliervermögens der Gelatine bewirkt. 



   Es wurde nun gefunden, dass man hämostatisch wirkende Pfropfen und Verbände aus löslicher
Gelatine dadurch herstellen kann, dass man einer
Gelatinelösung Thrombin zusetzt, die erhaltene
Lösung in Schaum   vei wandelt,   diesen Schaum bei tiefer Temperatur im Vakuum trocknet und den erhaltenen thrombinhaltigen Gelatine- schwamm in geeignete Form bringt. Gemäss diesem Verfahren werden hämostatisch wirkende
Pfropfen und Verbände erhalten, die aus einer leicht löslichen Gelatinethrombinmasse von watte- ähnlichem Aussehen bestehen. Diese Pfropfen und Verbände brauchen vorher nicht in Thrombin- lösung getaucht zu werden, sie können unmittelbar auf die Wunde, wo sie eine sehr rasche Hämostase bewirken, gelegt werden.

   Das aus der Wunde ausfliessende Blut wird in die schwammige Masse aufgesogen und löst den Gelatinebestandteil auf ; das dabei freiwerdende Thrombin bewirkt sofort die Verwandlung des Fibrinogens in Fibrin. Auf der Wunde bildet sich auf diese Weise ein Fibrin- film, welcher den Verschluss der Wunde bewirkt und den   Blutfluss   hemmt. Dieser Film haftet so stark auf der Oberfläche der Wunde, dass ein zusätzlicher Verband nicht notwendig ist. 



   In vitro wird die Wirksamkeit der Pfropfen folgendermassen gezeigt. 



   In einem Reagensglas (Durchmesser zirka 1 cm) werden einige Pfropfen zu einer Kolonne von ungefähr 5 cm Höhe lose eingestampft. Darauf werden 5 ccm 37 C warmes Plasma gegossen. Das Plasma wird in die schwammartige Masse eingesogen und gerinnt so schnell, dass das Reagensglas unmittelbar nach dem Eingiessen umgekehrt werden kann, ohne dass das Plasma abfliesst. 



   Der Gelatine-Thrombinmasse können verschiedene Antiseptica zugesetzt werden, ohne dass die Wirksamkeit der Verbände und Pfropfen dadurch leiden würde : Thymol, ein Gemisch von   p-Oxy-benzoesäuremethyl-und-propylester,   Sulfanilamide, wie 5-Sulfanilamido-3,4-dimethyl-isoxazol und vemarbungsbeschleunigende Sub- 
 EMI1.1 
 



   Die Gelatine übt auf das in Lösung befindliche Thrombin eine deutliche Schutzwirkung aus. So verliert eine wässerige,   50" Gelatine   enthaltende Thrombinlösung langsamer an Wirksamkeit als eine gleiche Lösung ohne Gelatine. 
 EMI1.2 
 
<tb> 
<tb> 



  Wässerige
<tb> Wässerige <SEP> Thrombin- <SEP> und
<tb> Thrombinlosung <SEP> Gelantinelosung
<tb> 5 <SEP> 500 <SEP> Th. <SEP> E <SEP> ccm <SEP> 7 <SEP> 500 <SEP> Th <SEP> E <SEP> ccm
<tb> nach <SEP> 24 <SEP> Stunden <SEP> 4.000 <SEP> 7.500
<tb> # <SEP> 48 <SEP> # <SEP> 2.500 <SEP> 5.500
<tb> # <SEP> 72 <SEP> # <SEP> 350 <SEP> 4.000
<tb> 
   Beispiel 1 : Zu l00ccm   destilliertem Wasser werden 5 g Blattgelatine zugesetzt, worauf auf   80   C   erwärmt wird. Die erhaltene etwas trübe Lösung wird warm durch ein Seitz-Filter filtriert und, wenn notwendig, auf einen pH-Wert von 6, 6 gestellt. 



   Nun werden zu 50 ccm der erhaltenen, auf 20   C abgekühlten Lösung 10 ccm einer Thrombinlösung mit einem Thrombingehalt von 10.000 Einheiten pro Kubikzentimeter zugesetzt. Diese Thrombinlösung Wird mit Hilfe eines Thrombinpräparates hergestellt, dessen Gehalt titrimetrisch zu 100 Th.   E   bestimmt wurde. Es bildet sich eine 

 <Desc/Clms Page number 2> 

   lochte Trübung)   die durch Sterilisierung mittels eines Seitz-Filters entfernt wird. 



    Die Hare Lösung wird durch Einblasen von steriler Luft mittels einer Sinterglasplatte und   durch Schlagen mit Hilfe eines   Schlagbesens   in einem voluminösen Schaum verwandelt. Dieser wird dann auf ein- Blatt ausgebreitet, bei tiefer Temperatur eingefroren und im Hochvakuum   bei-5"C entwässert.   



   Beispiel 2 : In 100 ccm warmem destilliertem Wasser werden 70 mg Thymol gelöst, der Lösung werden 5 Gelatine zugesetzt und das Ganze auf   80   C erwärmt. Im übrigen   wird wie im Beispiel 1 weiter gearbeitet. 



     Beispiel 3 : In 100 ccm destilliertem   Wasser werden 20 mg p-Oxy-benzoesäuremethylester und
80 mg p-Oxybenzoesäurepropylester gelöst. Die
Lösung wird mit 5   g Gelatine   versetzt, auf 80   C erwärmt und im übrigen wie im Beispiel 1 weiter- verarbeitet. 



   Beispiel 4 : 5g Gelatine werden mit   90ccm   destilliertem Wasser auf   800 C   erwärmt. In der warmen Lösung werden 2 fein pulverisierte
5-Sulfanilamido-3,   4-dimethyl-isoxazol   suspen- diert. Das PH wird durch Zusatz von 5 bis 10 ccm normaler Natronlauge auf 6, 6 gestellt, worauf sich das   SuKanilamid   auflöst. Man erwärmt auf   80 Q C   und verfährt im übrigen wie im Beispiel 1. 



   Beispiel 5 : In 100 ccm destilliertem Wasser werden 0,   28 g   Panthenol, [d   (+)--Dioxy-ss, ss-     dimethylbutyryl-Y'-oxypropylamid]   gelöst. Man setzt 5 Gelatine zu, erwärmt das Ganze auf   800 C   und verfährt im übrigen wie im Beispiel 1. 



   PATENTANSPRÜCHE : 
1. Verfahren zur Herstellung von hämostatisch wirkenden Pfropfen und Verbänden, dadurch gekennzeichnet, dass man einer Gelatinelösung Thrombin zusetzt, die erhaltene Lösung in
Schaum verwandelt, diesen Schaum bei tiefer Temperatur im Vakuum trocknet und den so erhaltenen thrombinhaltigen Gelatineschwamm in geeignete Form bringt.



   <Desc / Clms Page number 1>
 



  Process for the production of hemostatically acting plugs and bandages
In surgery, plugs and dressings that already have a hemostatic effect and consist of fibrin and cellulose derivative sponges and contain a thrombin solution are used. These plugs and dressings are made ready for use by immersing them in the thrombin solution immediately prior to use. This use makes it necessary that the sponges are made of water-insoluble material, since otherwise they would collapse when wetted with the thrombin solution. Such sponges have the major disadvantage that they are much more poorly absorbed by the organism than soluble substances.



   In order to counter this disadvantage, various authors use soluble gelatin jelly instead of these sponges, which they immerse in a thrombin solution shortly before use. The impregnation of such a jelly with the thrombin solution is difficult and takes place very slowly; Furthermore, the plugs and dressings, if they are soaked with the thrombin solution, cannot be stored for long, since the thrombin is not stable in the presence of water and very quickly loses its effectiveness. In addition, it was found that the thrombin causes a reduction in the gelling capacity of the gelatin.



   It has now been found that hemostatic plugs and dressings can be made from soluble
Gelatin can be made by having a
Gelatin solution thrombin adds the obtained
The solution is converted into foam, this foam is dried at low temperature in a vacuum and the resulting thrombin-containing gelatin sponge is brought into a suitable shape. According to this procedure, they become hemostatic
Obtain plugs and bandages, which consist of a readily soluble gelatin thrombin mass of cotton-like appearance. These plugs and dressings do not need to be immersed in thrombin solution beforehand; they can be placed directly on the wound, where they cause a very rapid hemostasis.

   The blood flowing out of the wound is absorbed into the spongy mass and dissolves the gelatin component; the thrombin that is released immediately causes the fibrinogen to be converted into fibrin. In this way, a fibrin film forms on the wound, which closes the wound and inhibits the flow of blood. This film adheres so strongly to the surface of the wound that an additional dressing is not necessary.



   In vitro the effectiveness of the plug is shown as follows.



   In a test tube (diameter approx. 1 cm) a few plugs are loosely tamped to form a column approx. 5 cm high. Then 5 cc of 37 C warm plasma are poured. The plasma is sucked into the spongy mass and coagulates so quickly that the test tube can be turned upside down immediately after pouring without the plasma flowing out.



   Various antiseptics can be added to the gelatin-thrombin mass without impairing the effectiveness of the dressings and plugs: thymol, a mixture of methyl and propyl p-oxybenzoate, sulfanilamides such as 5-sulfanilamido-3,4-dimethyl isoxazole and scarring-accelerating sub-
 EMI1.1
 



   The gelatine has a clear protective effect on the thrombin in solution. For example, an aqueous thrombin solution containing 50 "gelatin loses its effectiveness more slowly than an identical solution without gelatin.
 EMI1.2
 
<tb>
<tb>



  Watery
<tb> Aqueous <SEP> Thrombin- <SEP> and
<tb> thrombin solution <SEP> gelatin solution
<tb> 5 <SEP> 500 <SEP> Th. <SEP> E <SEP> ccm <SEP> 7 <SEP> 500 <SEP> Th <SEP> E <SEP> ccm
<tb> after <SEP> 24 <SEP> hours <SEP> 4,000 <SEP> 7,500
<tb> # <SEP> 48 <SEP> # <SEP> 2,500 <SEP> 5,500
<tb> # <SEP> 72 <SEP> # <SEP> 350 <SEP> 4,000
<tb>
   Example 1: 5 g of leaf gelatin are added to 100ccm of distilled water, and the mixture is then heated to 80.degree. The slightly cloudy solution obtained is filtered warm through a Seitz filter and, if necessary, adjusted to a pH of 6.6.



   10 cc of a thrombin solution with a thrombin content of 10,000 units per cubic centimeter are now added to 50 cc of the resulting solution, which has been cooled to 20 ° C. This thrombin solution is produced with the help of a thrombin preparation, the content of which was determined titrimetrically to be 100 Th. E. One forms

 <Desc / Clms Page number 2>

   perforated cloudiness) which is removed by sterilization using a Seitz filter.



    The Hare solution is transformed into a voluminous foam by blowing in sterile air through a sintered glass plate and by whipping with a whisk. This is then spread out on a sheet, frozen at a low temperature and drained in a high vacuum at -5 "C.



   Example 2: 70 mg of thymol are dissolved in 100 cc of warm distilled water, 5 gelatine are added to the solution and the whole is heated to 80.degree. Otherwise, the procedure is as in Example 1.



     Example 3: In 100 cc of distilled water, 20 mg of p-oxy-benzoic acid methyl ester and
80 mg of propyl p-oxybenzoate dissolved. The
5 g of gelatin are added to the solution, the mixture is heated to 80 ° C. and otherwise processed as in Example 1.



   Example 4: 5 g of gelatin are heated to 800 ° C. with 90 cc of distilled water. In the warm solution are 2 finely powdered
5-sulfanilamido-3, 4-dimethyl-isoxazole suspended. The pH is adjusted to 6.6 by adding 5 to 10 cc of normal sodium hydroxide solution, whereupon the SuKanilamide dissolves. It is heated to 80 ° C. and the rest of the procedure is as in Example 1.



   Example 5: 0.28 g of panthenol, [d (+) -dioxy-ss, s-dimethylbutyryl-Y'-oxypropylamide] are dissolved in 100 cc of distilled water. 5 gelatine are added, the whole is heated to 800 ° C. and the rest of the procedure is as in example 1.



   PATENT CLAIMS:
1. A process for the production of hemostatically acting plugs and dressings, characterized in that thrombin is added to a gelatin solution and the solution obtained is in
Foam is transformed, this foam is dried at low temperature in a vacuum and the resulting thrombin-containing gelatin sponge is brought into a suitable shape.


    

Claims (1)

2. Verfahren nach Anspruch 1, dadurch gekenn- zeichnet, dass man der Gelatinelösung Antiseptica zusetzt. 2. The method according to claim 1, characterized in that antiseptics are added to the gelatin solution. 3. Verfahren nach Anspruch l, dadurch gekenn- zeichnet, dass man der Gelatinelösung ver- narbungsbeschleunigende Stoffe zusetzt. 3. The method according to claim 1, characterized in that scarring-accelerating substances are added to the gelatin solution.
AT165549D 1947-06-03 1948-05-12 Process for the production of hemostatically acting plugs and bandages AT165549B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH2350347A CH264752A (en) 1947-06-03 1947-06-03 Process for the manufacture of carriers for pharmaceuticals.

Publications (1)

Publication Number Publication Date
AT165549B true AT165549B (en) 1950-03-15

Family

ID=38468378

Family Applications (1)

Application Number Title Priority Date Filing Date
AT165549D AT165549B (en) 1947-06-03 1948-05-12 Process for the production of hemostatically acting plugs and bandages

Country Status (6)

Country Link
US (1) US2558395A (en)
AT (1) AT165549B (en)
CH (1) CH264752A (en)
DE (1) DE915973C (en)
DK (1) DK73956C (en)
ES (1) ES183694A1 (en)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH303082A (en) * 1950-12-18 1954-11-15 Hoechst Ag Process for the production of a durable thrombin preparation of increased effectiveness.
US2642375A (en) * 1951-08-21 1953-06-16 Ethicon Suture Lab Inc Hemostatic compositions
US2712672A (en) * 1952-01-28 1955-07-12 Calcagno Luigi Process for preparing proteic sponges
US3234091A (en) * 1955-07-08 1966-02-08 Ciba Geigy Corp Shaped medicaments and process for their manufacture
US4006220A (en) * 1975-06-04 1977-02-01 Gottlieb Sheldon K Compositions and methods useful for repairing depressed cutaneous scars
DE2702356A1 (en) * 1977-01-21 1978-07-27 Gottlieb Sheldon K Repairing depressed cutaneous scars - using fibrin stabiliser and plasma
DE3065372D1 (en) * 1979-09-07 1983-11-24 Kingsdown Medical Consultants Wound dressing
US4292972A (en) * 1980-07-09 1981-10-06 E. R. Squibb & Sons, Inc. Lyophilized hydrocolloio foam
US4538603A (en) * 1982-04-22 1985-09-03 E. R. Squibb & Sons, Inc. Dressings, granules, and their use in treating wounds
US5039414A (en) * 1989-08-01 1991-08-13 Mueller Marc B Process for separating and/or recovering hydrocarbon oils from water using biodegradable absorbent sponges
DE4001714A1 (en) * 1990-01-22 1991-07-25 Beiersdorf Ag SELF-ADHESIVE BASED ON GELATINE
JPH0813750B2 (en) * 1990-03-01 1996-02-14 持田製薬株式会社 Oral thrombin formulation
US20110014290A1 (en) * 1995-09-15 2011-01-20 Boston Scientific Scimed, Inc. System and method for facilitating hemostasis with an absorbable sponge
US6183497B1 (en) * 1998-05-01 2001-02-06 Sub-Q, Inc. Absorbable sponge with contrasting agent
US6071301A (en) * 1998-05-01 2000-06-06 Sub Q., Inc. Device and method for facilitating hemostasis of a biopsy tract
US6071300A (en) * 1995-09-15 2000-06-06 Sub-Q Inc. Apparatus and method for percutaneous sealing of blood vessel punctures
US6162192A (en) 1998-05-01 2000-12-19 Sub Q, Inc. System and method for facilitating hemostasis of blood vessel punctures with absorbable sponge
US7435425B2 (en) * 2001-07-17 2008-10-14 Baxter International, Inc. Dry hemostatic compositions and methods for their preparation
US6066325A (en) 1996-08-27 2000-05-23 Fusion Medical Technologies, Inc. Fragmented polymeric compositions and methods for their use
US8303981B2 (en) 1996-08-27 2012-11-06 Baxter International Inc. Fragmented polymeric compositions and methods for their use
US8603511B2 (en) 1996-08-27 2013-12-10 Baxter International, Inc. Fragmented polymeric compositions and methods for their use
US7871637B2 (en) * 1996-08-27 2011-01-18 Baxter International Inc. Dry hemostatic compositions and methods for their preparation
US20010045575A1 (en) * 1998-05-01 2001-11-29 Mark Ashby Device and method for facilitating hemostasis of a biopsy tract
US6200328B1 (en) 1998-05-01 2001-03-13 Sub Q, Incorporated Device and method for facilitating hemostasis of a biopsy tract
US6610026B2 (en) 1998-05-01 2003-08-26 Sub-Q, Inc. Method of hydrating a sponge material for delivery to a body
US6315753B1 (en) * 1998-05-01 2001-11-13 Sub-Q, Inc. System and method for facilitating hemostasis of blood vessel punctures with absorbable sponge
US7625352B1 (en) 1998-05-01 2009-12-01 Sub-Q, Inc. Depth and puncture control for system for hemostasis of blood vessel
US6261679B1 (en) * 1998-05-22 2001-07-17 Kimberly-Clark Worldwide, Inc. Fibrous absorbent material and methods of making the same
EP1156741B1 (en) 1999-02-10 2010-12-22 Sub-Q, Inc. Device for facilitating hemostasis of a biopsy tract
US6984219B2 (en) 1999-09-23 2006-01-10 Mark Ashby Depth and puncture control for blood vessel hemostasis system
US7695492B1 (en) 1999-09-23 2010-04-13 Boston Scientific Scimed, Inc. Enhanced bleed back system
US6540735B1 (en) 2000-05-12 2003-04-01 Sub-Q, Inc. System and method for facilitating hemostasis of blood vessel punctures with absorbable sponge
US20020022822A1 (en) * 2000-07-14 2002-02-21 Cragg Andrew H. Sheath-mounted arterial plug delivery device
US7201725B1 (en) 2000-09-25 2007-04-10 Sub-Q, Inc. Device and method for determining a depth of an incision
US8187625B2 (en) 2001-03-12 2012-05-29 Boston Scientific Scimed, Inc. Cross-linked gelatin composition comprising a wetting agent
EP1406671A1 (en) * 2001-03-12 2004-04-14 Sub Q, Inc. Methods for sterilizing cross-linked gelatin compositions
US6863680B2 (en) 2001-11-08 2005-03-08 Sub-Q, Inc. System and method for delivering hemostasis promoting material to a blood vessel puncture site by fluid pressure
US7029489B1 (en) 2001-05-18 2006-04-18 Sub-Q, Inc. System and method for delivering hemostasis promoting material to a blood vessel puncture site
US7008440B2 (en) 2001-11-08 2006-03-07 Sub-Q, Inc. System and method for delivering hemostasis promoting material to a blood vessel puncture site by fluid pressure
US7037322B1 (en) 2001-11-08 2006-05-02 Sub-Q, Inc. System and method for delivering hemostasis promoting material to a blood vessel puncture with a staging tube
US7025748B2 (en) * 2001-11-08 2006-04-11 Boston Scientific Scimed, Inc. Sheath based blood vessel puncture locator and depth indicator
US7192436B2 (en) * 2001-11-08 2007-03-20 Sub-Q, Inc. Pledget-handling system and method for delivering hemostasis promoting material to a blood vessel puncture site by fluid pressure
US7037323B2 (en) * 2001-11-08 2006-05-02 Sub-Q, Inc. Pledget-handling system and method for delivering hemostasis promoting material to a blood vessel puncture site by fluid pressure
US7923431B2 (en) 2001-12-21 2011-04-12 Ferrosan Medical Devices A/S Haemostatic kit, a method of preparing a haemostatic agent and a method of promoting haemostatis
US20030155679A1 (en) * 2001-12-31 2003-08-21 Reeves William G. Method of making regenerated carbohydrate foam compositions
US20040102730A1 (en) * 2002-10-22 2004-05-27 Davis Thomas P. System and method for facilitating hemostasis of blood vessel punctures with absorbable sponge
US7455680B1 (en) 2002-11-04 2008-11-25 Boston Scientific Scimed, Inc. Apparatus and method for inhibiting blood loss
US7955353B1 (en) 2002-11-04 2011-06-07 Sub-Q, Inc. Dissolvable closure device
US8317821B1 (en) 2002-11-04 2012-11-27 Boston Scientific Scimed, Inc. Release mechanism
CA2509914A1 (en) * 2002-12-11 2004-06-24 Ferrosan A/S Gelatine-based materials as swabs
US8834864B2 (en) * 2003-06-05 2014-09-16 Baxter International Inc. Methods for repairing and regenerating human dura mater
US7927626B2 (en) * 2003-08-07 2011-04-19 Ethicon, Inc. Process of making flowable hemostatic compositions and devices containing such compositions
US7875043B1 (en) 2003-12-09 2011-01-25 Sub-Q, Inc. Cinching loop
WO2005072700A2 (en) * 2004-01-30 2005-08-11 Ferrosan A/S Haemostatic sprays and compositions
CN101001649B (en) * 2004-07-09 2011-08-31 弗罗桑医疗设备公司 Haemostatic composition comprising hyaluronic acid and its preparation method
CA2651941C (en) * 2006-05-31 2015-02-17 Baxter International Inc. Method for directed cell in-growth and controlled tissue regeneration in spinal surgery
TWI436793B (en) * 2006-08-02 2014-05-11 Baxter Int Rapidly acting dry sealant and methods for use and manufacture
US8623842B2 (en) 2006-09-27 2014-01-07 Hemostasis, Llc Hemostatic agent and method
MX2010004838A (en) 2007-10-30 2010-05-21 Baxter Int Use of a regenerative biofunctional collagen biomatrix for treating visceral or parietal defects.
CA2716872C (en) 2008-02-29 2015-02-10 Ferrosan Medical Devices A/S Device for promotion of hemostasis and/or wound healing
KR101541702B1 (en) 2008-03-03 2015-08-04 옴릭스 바이오파머슈티컬스 리미티드 A gelatin sponge comprising an active ingredient, its preparation and use
US9061087B2 (en) * 2008-03-04 2015-06-23 Hemostasis, Llc Method of making a hemostatic sponge wound dressing comprising subjecting the sponge to water vapor
US9039783B2 (en) * 2009-05-18 2015-05-26 Baxter International, Inc. Method for the improvement of mesh implant biocompatibility
JP5719355B2 (en) * 2009-06-16 2015-05-20 バクスター・インターナショナル・インコーポレイテッドBaxter International Incorp0Rated Hemostatic sponge
US20110052663A1 (en) * 2009-09-01 2011-03-03 Hemostasis, Llc Hemostatic Sponge with Enzyme and Method of Manufacture
KR101811070B1 (en) 2009-12-16 2017-12-20 백스터 인터내셔널 인코포레이티드 Hemostatic sponge
SA111320355B1 (en) 2010-04-07 2015-01-08 Baxter Heathcare S A Hemostatic sponge
AU2011260260B2 (en) 2010-06-01 2015-09-03 Baxter Healthcare S.A. Process for making dry and stable hemostatic compositions
EP2575775B1 (en) 2010-06-01 2018-04-04 Baxter International Inc. Process for making dry and stable hemostatic compositions
CA2801120C (en) 2010-06-01 2019-08-20 Baxter International Inc. Process for making dry and stable hemostatic compositions
KR102102002B1 (en) 2011-10-11 2020-04-20 백스터 인터내셔널 인코포레이티드 Hemostatic compositions
ES2938566T3 (en) 2011-10-11 2023-04-12 Baxter Int hemostatic compositions
ES2938541T3 (en) * 2011-10-11 2023-04-12 Baxter Int hemostatic composition
SA112330957B1 (en) 2011-10-27 2015-08-09 باكستر انترناشونال انك. Hemostatic compositions
RU2657955C2 (en) 2012-03-06 2018-06-18 Ферросан Медикал Дивайсиз А/С Pressurised container containing haemostatic paste
BR112014030962A2 (en) 2012-06-12 2017-06-27 Ferrosan Medical Devices As methods for preparing and reconstituting a dry composition suitable for use in haemostasis and wound healing, and hemostatic kit
RU2700162C2 (en) 2013-06-21 2019-09-13 Ферросан Медикал Дивайсиз А/С Dry composition expanded under vacuum and syringe for its preservation
EP3470094B1 (en) 2013-12-11 2020-07-22 Ferrosan Medical Devices A/S Dry composition comprising an extrusion enhancer
CA2960309A1 (en) 2014-10-13 2016-04-21 Ferrosan Medical Devices A/S Dry composition for use in haemostasis and wound healing
CN107206165B (en) 2014-12-24 2020-10-23 弗罗桑医疗设备公司 Syringe for holding and mixing first and second substances
AU2016290433B2 (en) 2015-07-03 2018-05-24 Ferrosan Medical Devices A/S Syringe for mixing two components and for retaining a vacuum in a storage condition
AU2017328480A1 (en) * 2016-09-14 2019-03-14 Ethicon, Inc. Stable pharmaceutical foam
IL247810A0 (en) 2016-09-14 2017-01-31 Omrix Biopharmaceuticals Ltd Stable pharmaceutical foam
WO2019215274A1 (en) 2018-05-09 2019-11-14 Ferrosan Medical Devices A/S Method for preparing a haemostatic composition

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE474093C (en) * 1927-07-30 1929-03-26 Erich Freund Dr Process for the production of hemostatic and wound-healing bandages and plasters
US2166074A (en) * 1937-04-09 1939-07-11 Sharp & Dohme Inc Gelatinous colloids
US2398077A (en) * 1940-04-29 1946-04-09 Parke Davis & Co Blood coagulating product and method of obtaining same

Also Published As

Publication number Publication date
US2558395A (en) 1951-06-26
DE915973C (en) 1954-08-02
CH264752A (en) 1949-10-31
ES183694A1 (en) 1948-07-04
DK73956C (en) 1952-03-31

Similar Documents

Publication Publication Date Title
AT165549B (en) Process for the production of hemostatically acting plugs and bandages
US4292972A (en) Lyophilized hydrocolloio foam
CN103520764B (en) Functional dressing, and preparation method and application thereof
DE3918628C2 (en) Process for the production of a cross-linked biopolymer based on collagen, implant from this biopolymer and process for the production of this implant
DE69032125T2 (en) GEL Wound Dressing Compositions And Method For Using Them
Maunsbach et al. Variations in fine structure of renal tubular epithelium under different conditions of fixation
US4587284A (en) Absorbent polymer material and its preparation
US3558771A (en) Process for using eggshell compositions for promoting wound healing
DE1620795C3 (en) Process for the production of optionally tanned and / or sterile collagen sponges
DE1617393A1 (en) Carrier for biologically active substances
EP0075791A1 (en) Absorbent wound dressing and processes for its production
CN104623718B (en) Chitosan petrolatum gauze and preparation method thereof
US20180117212A1 (en) Wound-healing and hemostatic sponge of squid ink polysaccharide/chitosan, preparation method and use thereof
EP0107055A2 (en) Artificial organs or membranes for medical use
CH646607A5 (en) HAEMOSTATIC AGENT AND METHOD FOR THE PRODUCTION THEREOF.
CN107693835A (en) A kind of polyvinyl alcohol/collagen/n-trimethyl chitosan chloride electrospun composite fibers film and preparation method thereof
JP2752782B2 (en) Soluble hemostatic fabric
KR960700766A (en) Pharmaceutical composition consisting of sponge material in which ester derivative of hyaluronic acid is combined with other pharmaceutically effective substances
DE1811290A1 (en) Process for the production of collagen fiber braids in the form of felt-like membranes or sponge-like layers
Cannon et al. Rate of epithelial regeneration: a clinical method of measurement, and the effect of various agents recommended in the treatment of burns
CH615099A5 (en)
US3842830A (en) Surgical dressing and method of forming the same
DE60205906T2 (en) Porous spongy cellulosic material for the treatment of injuries
DE849165C (en) Process for the production of threads, films and foams from fibrin
EP0165074A2 (en) Absorbent polymer material and its preparation